Jayanth R Arnold

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9352152/publications.pdf

Version: 2024-02-01

		361413	3	315739
53	1,533	20		38
papers	citations	h-index		g-index
				2120
55	55	55		2129
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	The Interfield Strength Agreement of Left Ventricular Strain Measurements at 1. <scp>5ÂT</scp> and <scp>3ÂT</scp> Using Cardiac <scp>MRI</scp> Feature Tracking. Journal of Magnetic Resonance Imaging, 2023, 57, 1250-1261.	3.4	6
2	Prevalence and Prognostic Significance of Microvascular Dysfunction in HeartÂFailure With Preserved EjectionAFraction. JACC: Cardiovascular Imaging, 2022, 15, 1001-1011.	5.3	25
3	Effects of late, repetitive remote ischaemic conditioning on myocardial strain in patients with acute myocardial infarction. Basic Research in Cardiology, 2022, 117, 23.	5.9	3
4	Prevalence of right ventricular dysfunction and prognostic significance in heart failure with preserved ejection fraction. International Journal of Cardiovascular Imaging, 2021, 37, 255-266.	1.5	12
5	Ischemia and Infarction in Isolated Chronic Total Coronary Artery Occlusion Assessed by Cardiovascular Magnetic Resonance. JACC: Cardiovascular Imaging, 2021, 14, 501-502.	5.3	0
6	Plasma Pâ€selectin is a predictor of mortality in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 2328-2333.	3.1	9
7	Early invasive versus non-invasive assessment in patients with suspected non-ST-elevation acute coronary syndrome. Heart, 2021, , heartjnl-2020-318778.	2.9	4
8	22â€Inter-field strength agreement of left ventricular strain and strain rate using Tissue Tracking and Al derived global longitudinal shortening. , 2021, , .		0
9	3â€Rationale and design of the Medical Research Council Precision medicine with Zibotentan in microvascular angina (PRIZE) trial MRI sub-study. , 2021, , .		0
10	Emerging glucose-lowering therapies: a guide for cardiologists. Heart, 2020, 106, 18-23.	2.9	6
11	Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction. International Journal of Cardiovascular Imaging, 2020, 36, 101-110.	1.5	35
12	Combined use of trimethylamine N-oxide with BNP for risk stratification in heart failure with preserved ejection fraction: findings from the DIAMONDHFpEF study. European Journal of Preventive Cardiology, 2020, 27, 2159-2162.	1.8	32
13	Cardiovascular magnetic resonance: applications and practical considerations for the general cardiologist. Heart, 2020, 106, 174-181.	2.9	51
14	Chronic infarct size after spontaneous coronary artery dissection: implications for pathophysiology and clinical management. European Heart Journal, 2020, 41, 2197-2205.	2.2	35
15	Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial. American Heart Journal, 2020, 229, 70-80.	2.7	40
16	Fibroblastâ€growthâ€factorâ€23 in heart failure with preserved ejection fraction: relation to exercise capacity and outcomes. ESC Heart Failure, 2020, 7, 4089-4099.	3.1	14
17	Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction. Biomarkers, 2020, 25, 556-565.	1.9	15
18	Inter-study repeatability of circumferential strain and diastolic strain rate by CMR tagging, feature tracking and tissue tracking in ST-segment elevation myocardial infarction. International Journal of Cardiovascular Imaging, 2020, 36, 1133-1146.	1.5	13

#	Article	IF	CITATIONS
19	Intra-study and inter-technique validation of cardiovascular magnetic resonance imaging derived left atrial ejection fraction as a prognostic biomarker in heart failure with preserved ejection fraction. International Journal of Cardiovascular Imaging, 2020, 36, 921-928.	1.5	6
20	Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach. PLoS ONE, 2020, 15, e0232280.	2.5	28
21	Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881986159.	3.2	16
22	Relationship Between Focal and DiffuseÂFibrosis Assessed by CMR and Clinical Outcomes in Heart Failure WithÂPreserved Ejection Fraction. JACC: Cardiovascular Imaging, 2019, 12, 2291-2301.	5.3	77
23	Haemodynamic effects of pharmacologic stress with adenosine in patients with left ventricular systolic dysfunction. International Journal of Cardiology, 2019, 278, 157-161.	1.7	4
24	Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction $\hat{a} \in \text{``implications for clinical trials.}$ Journal of Cardiovascular Magnetic Resonance, 2018, 20, 4.	3.3	62
25	Does stress perfusion imaging improve the diagnostic accuracy of late gadolinium enhanced cardiac magnetic resonance for establishing the etiology of heart failure?. BMC Cardiovascular Disorders, 2017, 17, 98.	1.7	8
26	Noninvasive Imaging Post–ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	1
27	Detection of Coronary Stenosis at RestÂUsingÂBOLD-CMR. JACC: Cardiovascular Imaging, 2017, 10, 600-601.	5.3	1
28	Comparison of global myocardial strain assessed by cardiovascular magnetic resonance tagging and feature tracking to infarct size at predicting remodelling following STEMI. BMC Cardiovascular Disorders, 2017, 17, 7.	1.7	22
29	Pheochromocytoma Is Characterized byÂCatecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, andÂMyocardial Dysfunction. Journal of the American College of Cardiology, 2016, 67, 2364-2374.	2.8	139
30	Multi-parametric cardiovascular magnetic resonance imaging detects subclinical myocardial involvement in patients diagnosed with phaeochromocytoma. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P271.	3.3	0
31	Residual Ischemia After Revascularization in Multivessel Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2013, 6, 237-245.	3.9	13
32	Patients With Syndrome X Have Normal Transmural Myocardial Perfusion and Oxygenation. Circulation: Cardiovascular Imaging, 2012, 5, 194-200.	2.6	52
33	Myocardial Oxygenation in Coronary Artery Disease. Journal of the American College of Cardiology, 2012, 59, 1954-1964.	2.8	77
34	With the "Universal Definition,―Measurement of Creatine Kinase-Myocardial Band Rather Than Troponin Allows More Accurate Diagnosis of Periprocedural Necrosis and Infarction After Coronary Intervention. Journal of the American College of Cardiology, 2011, 57, 653-661.	2.8	114
35	Early Diagnosis of Perioperative Myocardial Infarction After Coronary Bypass Grafting: A Study Using Biomarkers and Cardiac Magnetic Resonance Imaging. Annals of Thoracic Surgery, 2011, 92, 2046-2053.	1.3	47
36	Myocardial Perfusion Imaging After Coronary Artery Bypass Surgery Using Cardiovascular Magnetic Resonance. Circulation: Cardiovascular Imaging, 2011, 4, 312-318.	2.6	16

#	Article	IF	Citations
37	Systemic levels of endothelin correlate with systemic inflammation and not with myocardial injury or left ventricular ejection fraction in patients undergoing percutaneous coronary intervention and on-pump coronary artery bypass grafting. Interactive Cardiovascular and Thoracic Surgery, 2011, 13, 585-590.	1.1	11
38	Myocardial Injury following Coronary Artery Surgery versus Angioplasty (MICASA): a randomised trial using biochemical markers and cardiac magnetic resonance imaging. EuroIntervention, 2011, 6, 703-710.	3.2	30
39	Relationship Between Regional Myocardial Oxygenation and Perfusion in Patients With Coronary Artery Disease. Circulation: Cardiovascular Imaging, 2010, 3, 32-40.	2.6	92
40	Adenosine Stress Myocardial Contrast Echocardiography for the Detection of Coronary Artery Disease. JACC: Cardiovascular Imaging, 2010, 3, 934-943.	5.3	44
41	Tolerance and safety of adenosine stress perfusion cardiovascular magnetic resonance imaging in patients with severe coronary artery disease. International Journal of Cardiovascular Imaging, 2009, 25, 277-283.	1.5	43
42	GH replacement in patients with nonâ€functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clinical Endocrinology, 2009, 70, 435-438.	2.4	47
43	Should patients undergoing PCI still be consented for emergency bypass?. International Journal of Cardiology, 2009, 132, 447-448.	1.7	1
44	Left ventricular lipomatous metaplasia following myocardial infarction. International Journal of Cardiology, 2009, 137, e11-e12.	1.7	12
45	The role of Intravascular Ultrasound in the management of spontaneous coronary artery dissection. Cardiovascular Ultrasound, 2008, 6, 24.	1.6	105
46	Long term outcome of elective day case percutaneous coronary intervention in patients with stable angina. International Journal of Cardiology, 2008, 128, 272-274.	1.7	12
47	Diabetic cardiomyopathy: a controversial entity. European Heart Journal, 2008, 29, 564-564.	2.2	6
48	Redefining cardiomyopathies: the role of cardiovascular magnetic resonance imaging. European Heart Journal, 2007, 28, 3094-3095.	2.2	0
49	GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clinical Endocrinology, 2006, 64, 556-560.	2.4	108
50	Ventricular septal rupture following abciximab infusion. European Journal of Echocardiography, 2006, 9, 60-2.	2.3	5
51	Thrombotic occlusion of a drug-eluting stent - is IVUS mandatory. Journal of Invasive Cardiology, 2006, 18, E238-40.	0.4	2
52	Is Helicobacter pylori a Factor in Coronary Atherosclerosis?. Journal of Clinical Microbiology, 1999, 37, 1651-1651.	3.9	20
53	Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis. Cardiac Failure Review, 0, 8, .	3.0	12